The lysine deacetylase inhibitor givinostat inhibits β-cell IL-1β induced IL-1β transcription and processing

類似資料

• Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection
  著者:: Christensen, Dan Ploug, 等
  出版事項: (2014)
• Histone Deacetylase (HDAC) Inhibition as a Novel Treatment for Diabetes Mellitus
  著者:: Christensen, Dan P, 等
  出版事項: (2011)
• HDAC Inhibitor-Mediated Beta-Cell Protection Against Cytokine-Induced Toxicity Is STAT1 Tyr701 Phosphorylation Independent
  著者:: Dahllöf, Mattias S., 等
  出版事項: (2015)
• Pharmacokinetics, Safety and Inducible Cytokine Responses during a Phase 1 Trial of the Oral Histone Deacetylase Inhibitor ITF2357 (Givinostat)
  著者:: Furlan, Antonio, 等
  出版事項: (2011)
• The Oral Histone Deacetylase Inhibitor ITF2357 Reduces Cytokines and Protects Islet β Cells In Vivo and In Vitro
  著者:: Lewis, Eli C, 等
  出版事項: (2011)